Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 11/20 | 0.51 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.51 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.51 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | PREP | P48147 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19055875 | 1.00 | DPP4 (0.51) | DPP4DPP8DPP9CTSKHPGD | |
| SCHEMBL82202 | 1.00 | DPP4 (0.51) | DPP4DPP8DPP9CTSKHPGD | |
| SCHEMBL2896482 | 0.95 | DPP4 (0.56) | DPP4DPP8DPP9CTSKPREP | |
| SCHEMBL240005 | 0.95 | DPP4 (0.56) | DPP4DPP8DPP9CTSKPREP | |
| SCHEMBL1357066 | 0.95 | DPP4 (0.56) | DPP4DPP8DPP9CTSKPREP | |
| SCHEMBL6213019 | 0.91 | HSD17B10 (0.52) | DPP4DPP8DPP9CTSK | |
| SCHEMBL6166916 | 0.89 | CTSK (0.49) | DPP4DPP8DPP9CTSK | |
| SCHEMBL16067363 | 0.89 | CTSK (0.49) | DPP4DPP8DPP9CTSK | |
| SCHEMBL7380781 | 0.86 | HPGD (0.48) | CTSKHPGDPREP | |
| SCHEMBL9555116 | 0.86 | HPGD (0.48) | CTSKHPGDPREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581525-A2 | COMPOUNDS HAVING AN ACTIVITY AT METABOTROPIC GLUTAMATE RECEPTORS | AstraZeneca AB (SE) | 2005-10-05 | — | — | EP | claimed |
| US-20040106607-A1 | New compounds | ASTRAZENECA AB AND NPS PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | claimed |
| WO-2004014902-A2 | COMPOUNDS HAVING AN ACTIVITY AT METABOTROPIC GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2004-02-19 | — | — | WO | claimed |
| US-20260103459-A1 | SUBSTITUTED AZACYLES AS TRPM8 MODULATORS | GIVAUDAN SA (CH) | 2026-04-16 | — | — | US | disclosed |
| US-12528801-B2 | Substituted azacyles as TRPM8 modulators | GIVAUDAN SA (CH) | 2026-01-20 | — | — | US | disclosed |
| CN-114555594-B | Substituted azacycles as TRMP modulators | 奇华顿股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20240327392-A1 | HETEROCYCLOALKYL-SUBSTITUTED POLYHETEROAZOLE DERIVATIVES AS MEDICAMENTS FOR TREATING AND/OR PREVENTING RS VIRUS INFECTIONS | ALBIUS SCIENCES ALPHA PRIVATE LIMITED (SG) | 2024-10-03 | — | — | US | disclosed |
| EP-4361148-A1 | HETEROCYCLOALKYL-SUBSTITUTED POLYHETEROAZOLE DERIVATIVE AS MEDICAL DRUG FOR TREATMENT AND/OR PREVENTION OF RS VIRUS INFECTIOUS DISEASE | Albius Sciences Alpha Private Limited (SG) | 2024-05-01 | — | — | EP | disclosed |
| US-20240132487-A1 | SUBSTITUTED AZACYLES AS TRMP8 MODULATORS | GIVAUDAN SA (CH) | 2024-04-25 | — | — | US | disclosed |
| CN-113993850-B | Modulators of integrated stress response pathways | 埃沃特克国际有限责任公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117736182-A | MetTL3 inhibitors and uses thereof | 成都先导药物开发股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2007063012-A1 | HETEROARYL SUBSTITUTED PIPERIDINE DERIVATIVES AS L-CPT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| US-20070129544-A1 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | US | disclosed |
| EP-1716143-A1 | POLYHETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2006-11-02 | — | — | EP | disclosed |
| US-7074809-B2 | Compounds | ASTRAZENECA AB (SE) | 2006-07-11 | — | — | US | disclosed |
| US-20060025414-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-02-02 | — | — | US | disclosed |
| EP-1581525-A2 | COMPOUNDS HAVING AN ACTIVITY AT METABOTROPIC GLUTAMATE RECEPTORS | AstraZeneca AB (SE) | 2005-10-05 | — | — | EP | disclosed |
| WO-2005080386-A1 | POLYHETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20040106607-A1 | New compounds | ASTRAZENECA AB AND NPS PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | disclosed |
| WO-2004014902-A2 | COMPOUNDS HAVING AN ACTIVITY AT METABOTROPIC GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103459-A1 | SUBSTITUTED AZACYLES AS TRPM8 MODULATORS | TRPM8, TRPM7, TRPM5 | DPP4 3805/4885DPP8 474/4885DPP9 2470/4885 |
| US-20240327392-A1 | HETEROCYCLOALKYL-SUBSTITUTED POLYHETEROAZOLE DERIVATIVES AS MEDICAMENTS FOR TREATING AND/OR PREVENTING RS VIRUS INFECTIONS | RSU1, TSLP, HAVCR2 | DPP4 137/4885DPP8 794/4885DPP9 1035/4885 |
| US-20060025414-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM3, GRM1, GRM4 | DPP4 890/4885DPP8 2130/4885DPP9 2419/4885 |
| US-20240132487-A1 | SUBSTITUTED AZACYLES AS TRMP8 MODULATORS | TRPM8, TRPM7, TRPM5 | DPP4 3899/4885DPP8 263/4885DPP9 1647/4885 |
| US-20040106607-A1 | New compounds | MTX1, MLX, TPX2 | DPP4 1554/4885DPP8 3847/4885DPP9 3604/4885 |
| US-12528801-B2 | Substituted azacyles as TRPM8 modulators | TRPM8, TRPM7, TRPM4 | DPP4 4131/4885DPP8 762/4885DPP9 3159/4885 |
| US-20070129544-A1 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | CPT1A, CPT1B, CPT2 | DPP4 630/4885DPP8 1357/4885DPP9 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.